WallStreetZenWallStreetZen

NASDAQ: ANL
Adlai Nortye Ltd Stock

$3.49+0.24 (+7.38%)
Updated Jul 15, 2024
ANL Price
$3.49
Fair Value Price
$1.45
Market Cap
$128.69M
52 Week Low
$3.01
52 Week High
$19.30
P/E
-0.48x
P/B
1.62x
P/S
25.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.00M
Earnings
-$104.87M
Gross Margin
100%
Operating Margin
-2,068.74%
Profit Margin
-2,097.4%
Debt to Equity
0.64
Operating Cash Flow
-$57M
Beta
-0.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ANL Overview

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ANL ($3.49) is overvalued by 140.68% relative to our estimate of its Fair Value price of $1.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANL ($3.49) is not significantly undervalued (140.68%) relative to our estimate of its Fair Value price of $1.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANL due diligence checks available for Premium users.

Be the first to know about important ANL news, forecast changes, insider trades & much more!

ANL News

Valuation

ANL fair value

Fair Value of ANL stock based on Discounted Cash Flow (DCF)
Price
$3.49
Fair Value
$1.45
Overvalued by
140.62%
ANL ($3.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANL ($3.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ANL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.48x
Industry
-20.45x
Market
31.91x

ANL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.62x
Industry
6.46x
ANL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ANL's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ANL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ANL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$130.2M
Liabilities
$50.8M
Debt to equity
0.64
ANL's short-term assets ($101.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANL's short-term assets ($101.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
ANL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ANL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ANL$128.69M+7.42%-0.48x1.62x
ATHA$128.78M+1.20%-1.10x1.21x
IMAB$131.61M-5.23%-0.67x0.55x
CRVS$125.10M-2.44%-3.92x3.75x
RAPT$124.61M+4.08%-1.16x0.95x

Adlai Nortye Stock FAQ

What is Adlai Nortye's quote symbol?

(NASDAQ: ANL) Adlai Nortye trades on the NASDAQ under the ticker symbol ANL. Adlai Nortye stock quotes can also be displayed as NASDAQ: ANL.

If you're new to stock investing, here's how to buy Adlai Nortye stock.

What is the 52 week high and low for Adlai Nortye (NASDAQ: ANL)?

(NASDAQ: ANL) Adlai Nortye's 52-week high was $19.30, and its 52-week low was $3.01. It is currently -81.91% from its 52-week high and 15.98% from its 52-week low.

How much is Adlai Nortye's stock price per share?

(NASDAQ: ANL) Adlai Nortye stock price per share is $3.49 today (as of Jul 15, 2024).

What is Adlai Nortye's Market Cap?

(NASDAQ: ANL) Adlai Nortye's market cap is $128.69M, as of Jul 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Adlai Nortye's market cap is calculated by multiplying ANL's current stock price of $3.49 by ANL's total outstanding shares of 110,700,805.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.